Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations

Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some. The recent approval of nivolumab in combination with relatlimab (nivolumab-relatlimab) added a third immunotherapy option for first-l...

Full description

Saved in:
Bibliographic Details
Main Authors: Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:EJC Skin Cancer
Subjects:
Melanoma
Immune checkpoint inhibitors
First-line treatment
Treatment selection
Online Access:http://www.sciencedirect.com/science/article/pii/S2772611825000060
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items